Is China's Evergrande too big to fail and what does Evergrande's debt crunch mean for investors? What are the changing regulations by the US' FDA for Pfizer booster shots?
What do you think of Hong Kong's SPAC listings?
Michelle Martin and Ryan Huang go beyond the headlines and market buzz in this edition of Market View.